What is REGN's current stock price?

As of now, REGN is trading at $741.45, with a daily change of -1.07%.

What are the risks associated with REGN stock?

REGN has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN

Regeneron Pharma

$741.45

-$7.99 | -1.07%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$821.11

MKT CAP

$77.93B

52W Low

$476.49

VOL

$1.12M

P/E Ratio

17.74

AVG VOL

$851.34K

RSI

45.02

TREND

Sideways

REGN Stock IQ

Login to see Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

REGN Target Price

Login to display

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Rewards

Outperform the market

REGN Price Performance

$771.87 (-3.94%)

$642.25 (+15.45%)

$573.38 (+29.31%)

$674.27 (+9.96%)

1year

6month

3month

1month

REGN Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

REGN Analysts Opinion

REGN Analysts opinion is negative but has improved from the past 3 months

REGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

71%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

77%

100%

0%

REGN Street Sentiment

REGN Street Sentiment is bullish and have negative views on the near-term outlook

REGN Risk Level

REGN has Low risk level

Low

LOW

HIGH

REGN Performance Sentiment

Sentiments overview associated with events and the stock performance

71%

20%

Positive

Negative

32 out of 45
events present

9 out of 45
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$751.13

Resistance
Price

$733.04

Current Price Range

$812.27

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

9

0

Date

Action

Rating

Firm

Jan 09, 2026

Upgrade

Buy

Zacks

Jan 07, 2026

Upgrade

Buy

B of A Securities

Jan 07, 2026

Upgrade

Buy

BofA

Nov 24, 2025

Initiate

Buy

HSBC

Oct 30, 2025

Reiterate

Buy

Citigroup

Linked to REGN

Close Price

Change

SNY

Sanofi

47.04

+1.82%

NVS

Novartis AG

148.68

-0.16%

TEVA

Teva Pharma

34.08

+3.05%

MRK

Merck Company

110.27

+1.80%

OPK

Opko Health

1.26

-0.79%

Recently Viewed

Close Price

Change

REGN

Regeneron Pharma

741.45

-1.07%

AQB

AquaBounty Technolog

0.91

-5.21%

CIEN

Ciena

251.81

-0.64%

LNC

Lincoln National

41.61

-0.02%

BZUN

Baozun Inc. American

2.68

-2.90%

REGN Latest Analysis +

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates. Regeneron (REGN) delivered earnings and revenue surprises of 8.32% and 1.77% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Fri Jan 30, 2026

$741.45 | -1.07%

Earnings

Regeneron Posts Lower Eylea Sales Amid Rising Competition Plans $2 Billion New Factory. ) on Friday reported fourth-quarter adjusted earnings of $11.44 per share down 5% year-over-year beating the.Thecompany reported salesof $3.88 billion up 3% year over year beating the .In the quarter United States net sales for Eylea HDand Eyleadecreased 28% year-over-year to $1.08billion including $506 million from Eylea HD and $577 million from Eylea. were negatively impacted by lower sales volumes as a res

Fri Jan 30, 2026

$741.45 | -1.07%

Activity

Potential

Regeneron Handily Beat Fourth-Quarter Forecasts — Heres Why Shares Fell.

Fri Jan 30, 2026

$741.45 | -1.07%

Earnings

Regeneron Pharmaceuticals beats top-line and bottom-line estimates. initiates FY26 outlook.

Fri Jan 30, 2026

$741.45 | -1.07%

Earnings

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings. These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call. ) will release earnings results for its fourth quarter before the opening bell on Friday Jan. 30.Analysts expect the Tarrytown New York-based company to report quarterly earnings at $10.74 per share down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals'. quarterly revenue is $3.79 billion versus $3.79 billion a y

Fri Jan 30, 2026

$741.45 | -1.07%

Activity

Earnings

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug.

Tue Jan 27, 2026

$771.25 | +1.13%

Activity

Momentum

Regeneron (REGN) Posted Solid Quarterly Results Eyes 2026 Pipeline Catalysts.

Tue Jan 27, 2026

$771.25 | +1.13%

Earnings

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?. Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fri Jan 23, 2026

$753.55 | -0.26%

Earnings

BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions. SAN JOSE Calif. Jan. 20 2026 (GLOBE NEWSWIRE) -- BrightInsight a leader in digital health solutions today announced a new investment round of $13 million from existing and new investors including Eclipse General Catalyst Insight Partners Mayo Clinic and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight'.s AI-enabled

Tue Jan 20, 2026

$733.78 | +0.10%

Activity

This Is What Whales Are Betting On Regeneron Pharmaceuticals. Investors with a lot of money to spend have taken a ish stance on ).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with REGN it often means somebody knows something is about to happen.So how do we know what these investors

Wed Jan 14, 2026

$754.14 | -0.63%

Activity

FAQ About REGN Stock Insights

What is REGN current stock price?

What are REGN stock strengths?

What is REGN Risk Level?

What is REGN market cap and volume?

What is REGN current Stock IQ?

Should I buy REGN stock right now?

Is REGN a Strong Buy right now?

What does a 'Strong Buy' rating mean for REGN?

What does a 'Strong Sell' rating mean for REGN?

What factors influence REGN's Stock IQ?

Explore our REGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored REGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our REGN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

REGN

Regeneron Pharma

Set Alerts

Current Price

$741.45

-$7.99 | -1.07%

52W High

$821.11

MKT CAP

$77.93B

52W Low

$476.49

VOL

$1.12M

P/E Ratio

17.74

AVG VOL

$851.34K

RSI

45.02

TREND

Sideways

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Stock Insights

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Rewards

Outperform the market

Linked to REGN

Symbol

Close

Change

SNY

Sanofi

47.04

+1.82%

NVS

Novartis AG

148.68

-0.16%

TEVA

Teva Pharma

34.08

+3.05%

MRK

Merck Company

110.27

+1.80%

OPK

Opko Health

1.26

-0.79%

REGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

71%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

77%

100%

0%

REGN Street Sentiment

REGN Street Sentiment is bullish and have negative views on the near-term outlook

REGN Risk Level

REGN has Low risk level

Low

LOW

HIGH

REGN Performance Sentiment

Sentiments overview associated with events and the stock performance.

71%

20%

Positive

Negative

32 out of 45
events present

9 out of 45
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$751.13

Resistance
Price

$733.04

Current Price Range

$812.27

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

9

0

Date

Action

Rating

Firm

Jan 09, 2026

Upgrade

Buy

Zacks

Jan 07, 2026

Upgrade

Buy

B of A Securities

Jan 07, 2026

Upgrade

Buy

BofA

Nov 24, 2025

Initiate

Buy

HSBC

Oct 30, 2025

Reiterate

Buy

Citigroup

Oct 30, 2025

Reiterate

Buy

Guggenheim

Oct 30, 2025

Reiterate

Overweight

Cantor Fitzgerald

REGN Stock IQ

Login to unlock Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

REGN Latest Analysis

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates. Regeneron (REGN) delivered earnings and revenue surprises of 8.32% and 1.77% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Fri Jan 30, 2026

$741.45 | -1.07%

Earnings

Regeneron Posts Lower Eylea Sales Amid Rising Competition Plans $2 Billion New Factory. ) on Friday reported fourth-quarter adjusted earnings of $11.44 per share down 5% year-over-year beating the.Thecompany reported salesof $3.88 billion up 3% year over year beating the .In the quarter United States net sales for Eylea HDand Eyleadecreased 28% year-over-year to $1.08billion including $506 million from Eylea HD and $577 million from Eylea. were negatively impacted by lower sales volumes as a res

Fri Jan 30, 2026

$741.45 | -1.07%

Activity

Potential

Regeneron Handily Beat Fourth-Quarter Forecasts — Heres Why Shares Fell.

Fri Jan 30, 2026

$741.45 | -1.07%

Earnings

Regeneron Pharmaceuticals beats top-line and bottom-line estimates. initiates FY26 outlook.

Fri Jan 30, 2026

$741.45 | -1.07%

Earnings

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings. These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call. ) will release earnings results for its fourth quarter before the opening bell on Friday Jan. 30.Analysts expect the Tarrytown New York-based company to report quarterly earnings at $10.74 per share down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals'. quarterly revenue is $3.79 billion versus $3.79 billion a y

Fri Jan 30, 2026

$741.45 | -1.07%

Activity

Earnings

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug.

Tue Jan 27, 2026

$771.25 | +1.13%

Activity

Momentum

Regeneron (REGN) Posted Solid Quarterly Results Eyes 2026 Pipeline Catalysts.

Tue Jan 27, 2026

$771.25 | +1.13%

Earnings

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?. Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fri Jan 23, 2026

$753.55 | -0.26%

Earnings

BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions. SAN JOSE Calif. Jan. 20 2026 (GLOBE NEWSWIRE) -- BrightInsight a leader in digital health solutions today announced a new investment round of $13 million from existing and new investors including Eclipse General Catalyst Insight Partners Mayo Clinic and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight'.s AI-enabled

Tue Jan 20, 2026

$733.78 | +0.10%

Activity

This Is What Whales Are Betting On Regeneron Pharmaceuticals. Investors with a lot of money to spend have taken a ish stance on ).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with REGN it often means somebody knows something is about to happen.So how do we know what these investors

Wed Jan 14, 2026

$754.14 | -0.63%

Activity

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of REGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our REGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

REGN Stock trends

REGN Stock performance

REGN Stock analysis

REGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN Stock IQ

REGN Target Price

REGN Analysts Opinion

REGN Street Sentiment

REGN Risk Level

REGN Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our REGN Stock insights

Receive our REGN Daily Alerts

REGN Street Sentiment

REGN Risk Level

Key Price Levels

Latest Analyst Actions

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of REGN. We're here to help you make informed investment decisions today.

Receive our REGN Daily Alerts

REGN Alerts